Keywords: UK, NICE, Eli Lilly, Alimta, NSCLC, Pemetrexed, Lung cancer

Data uncertainties mean NICE unable to recommend pemetrexed for NSCLC maintenance treatment

Article | 17 December 2009

Print This

Giving an initial negative opinion, the UK’s National Institute for Health and Clinical Excellence (NICE) is currently appraising the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in